Magnus E.
- Country
- Sweden
- Department
- Department of Internal Medicine
Research Overview
- Efficacy of Imatinib in Acute Ischemic Stroke: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial
- A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack
- Evaluation of Clopidogrel, Atorvastatin, Rosuvastatin, and Acetylsalicylic Acid in Covert Brain Infarction: A Multicenter Randomized Controlled Trial
Data & Insights
Has run more than one trial at 29 of 310 partner sites.
Specializations
Cerebrovascular Disorders
This investigator specializes in treating acute stroke conditions, with particular focus on both hemorrhagic and ischemic stroke management.
- Intracerebral Hemorrhage (ICH) Treatment
- Acute Ischemic Stroke Intervention
- Emergency Stroke Care
Their research interests encompass innovative therapeutic approaches in acute stroke treatment, including hemorrhage management and neuroprotective strategies.
Therapeutic Interventions
The investigator focuses on evaluating novel therapeutic agents for stroke treatment, including tranexamic acid and imatinib applications in acute settings.
- Hemorrhage Control Strategies
- Neuroprotective Treatments
- Early Intervention Protocols
Their work centers on time-critical therapeutic interventions within the acute phase of stroke onset.
Clinical Outcomes
The investigator specializes in assessing functional outcomes and mortality rates in acute stroke patients.
- Early Mortality Prevention
- Long-term Functional Recovery
- Treatment Efficacy Assessment
Their research emphasizes the evaluation of therapeutic interventions' impact on patient survival and recovery.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.